A promising development for OC patien... - SHARE Ovarian Can...

SHARE Ovarian Cancer Support

2,750 members981 posts

A promising development for OC patients...

shyney profile image
2 Replies

Here’s a recent article that shows a promising development for ovarian cancer patients-- wanted to share!

A study on a PARP inhibitor, niraparib, showed that “Niraparib significantly improved progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, regardless of BRCA mutation status.”

The median progression-free survival for patients given niraparib was 2 years, as opposed to 5.5 months.

PARP inhibitors work by targeting “HRD, a defect in DNA repair that, if unchecked, allows cancer to grow, proliferate, and acquire the biological immortality that characterizes fatal ovarian cancer.”

See the full article here: medpagetoday.com/meetingcov...

Written by
shyney profile image
shyney
To view profiles and participate in discussions please or .
Read more about...
2 Replies
SBlau profile image
SBlauPartner

Hi Miyoshi, Thanks for sending your address. We will send you a book in the next few weeks. Feel free to delete this post, if you want since the post is public. Thanks!

miyoshi profile image
miyoshi in reply to SBlau

Thank you!

You may also like...

Stage 3c OC, ca125 rising slowly

here. My mother was diagnosed with stage 3c ovarian cancer in 2017, she had a very long debunking...

Seeking advice from Lynparza, Rubraca or Zejula patients.

hours/days researching survival stories as I enter the second year of parp-inhibitor treatments....

Lynparza and OC Recurrences

oncologist told me that another recurrence is in the cancer's favor and it's really a matter of...

Stomach pain after chemo in stage 3 OC

wondering if it is normal? Could be a good sign that cancer cells are dieing. However, her pain is...

Zejula parp inhibitor

I just had a metastatic recurrence of my ovarian cancer for which I was in NED for 2 Yrs and...